Recent studies have found that CSF-1 in the tumor microenvironment could combine with its receptor CSF-1R in liver cancer, ureteral cancer, pancreatic cancer, gastric cancer, intestinal cancer and other malignant tumors 7, 13-17, and participate in biological processes such as promoting tumor cell proliferation, inhibiting tumor cell apoptosis and inducing blood vessel formation, etc. Targeted inhibition of the CSF-1/CSF-1R signal axis has broad application prospects in cancer immunotherapy 18-20. This evidence concerns the gene CSF1 and familial pancreatic carcinoma.